Antibody response after second BNT162b2 dose in allogeneic HSCT recipients

Lancet. 2021 Jul 24;398(10297):298-299. doi: 10.1016/S0140-6736(21)01594-4. Epub 2021 Jul 13.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Viral / immunology*
  • BNT162 Vaccine
  • COVID-19 / prevention & control
  • COVID-19 Vaccines / immunology*
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Immunocompromised Host*
  • Pandemics
  • SARS-CoV-2

Substances

  • Antibodies, Viral
  • COVID-19 Vaccines
  • BNT162 Vaccine